Quarterly ResultJul 14, 2026, 07:46 AM
HCA Healthcare Previews Q2 2026 Results, Revises 2026 Guidance
AI Summary
HCA Healthcare announced preliminary financial and operating results for the second quarter ended June 30, 2026, reporting increased revenue and net income compared to the prior year. The company also revised its full-year 2026 guidance downwards, citing an unfavorable payer mix shift due to increased uninsured volume, which negatively impacted income by approximately $400 million in Q2. This was partially offset by a $400 million benefit from Medicaid Supplemental Payment Programs.
Key Highlights
- Preliminary Q2 2026 revenue approximated $20.230 billion, up from $18.605 billion in Q2 2025.
- Preliminary Q2 2026 net income was $1.699 billion, or $7.62 per diluted share, vs $1.653 billion, or $6.83 per diluted share in Q2 2025.
- Preliminary Q2 2026 Adjusted EBITDA approximated $4.027 billion, compared to $3.849 billion in Q2 2025.
- Revised 2026 revenue guidance to $77.000-$79.500 billion from $76.500-$80.000 billion.
- Revised 2026 diluted EPS guidance to $28.70-$30.50 from $29.10-$31.50.
- Payer mix shift due to uninsured volume had an unfavorable impact of approximately $400 million on Q2 income.
- Recognized approximately $400 million of incremental net benefit from Medicaid Supplemental Payment Programs in Q2.
- Same facility admissions increased 2.5% and ER visits increased 3.6% in Q2 2026.
Price Impact
More from HCA